<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25184923</article-id>
      <article-id pub-id-type="pmc">4155962</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20143058</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Vulvar vitiligo-like depigmentation and multiple halos of hypomelanosis
at the trunk following treatment with imiquimod 5% cream for vulvar condylomata:
casual or related events?<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Serra</surname>
            <given-names>Ma&#xED;ra Chiarelli</given-names>
          </name>
          <xref ref-type="corresp" rid="c01"/>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Menicanti</surname>
            <given-names>Claudia</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pennacchioli</surname>
            <given-names>Elisabetta</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tosti</surname>
            <given-names>Giulio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> Istituto Europeo di Oncologia -Divisione Melanoma- Milano,
Italia.</aff>
      <aff id="aff02"><label>2</label> Fondazione IRCSS Ca' Granda - Ospedale Maggiore Policlinico.
Dipartimento di Fisiopatologia Medico-Chirurgica - Milano, Italia.</aff>
      <aff id="aff03"><label>3</label> Universit&#xE0; degli Studi di Milano- Milano, Italia.</aff>
      <aff id="aff04"><label>4</label> Universita degli Studi di Ferrara - Ferrara, Italia.</aff>
      <author-notes>
        <corresp id="c01"><italic>MAILING ADDRESS:</italic> Ma&#xED;ra Chiarelli Serra, Via Ripamonti, 435, 20141 -
Milano. E-mail: <email>m.chiarelliserra@gmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2014</year>
      </pub-date>
      <volume>89</volume>
      <issue>5</issue>
      <fpage>806</fpage>
      <lpage>807</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>9</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2014 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A 25-year-old Caucasian female with multiple genital warts involving the vulvar area
was treated with imiquimod 5% cream. During follow-up the patient developed areas of
hypopigmentation at the site of application of imiquimod cream and areas of
hypomelanosis around multiple preexisting nevi of the trunk. At 18 months follow-up
genital depigmentation persisted and halo nevi of the trunk were still present.
Different mechanisms of imiquimod-induced depigmentation have been reported. Halo
nevi are considered expression of an autoimmune response. In the case presented here,
it might be conceivable that both vitiligo-like depigmentation at the site of
application and halo of hypomelanosis around melanocytic nevi have been induced by
the same immunologic mechanism elicited by topical application of imiquimod.</p>
      </abstract>
      <kwd-group>
        <kwd>Condylomata acuminata</kwd>
        <kwd>Immune system</kwd>
        <kwd>Immune system phenomena</kwd>
        <kwd>Nevus, halo</kwd>
        <kwd>Vitiligo</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Imiquimod 5% cream is currently approved for topical treatment of genital warts,
superficial basal cell carcinoma and actinic keratoses. So far, several cases of
vitiligo-like imiquimod-induced depigmentation have been reported.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup>
The present case report refers to the observation of vulvar depigmentation and onset of
multiple halos of hypomelanosis around several melanocytic nevi of the trunk following
treatment with imiquimod 5% cream for vulvar condylomata (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>).<sup><xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Multiple halos of depigmentation at site of Imiquimod application</p>
        </caption>
        <graphic xlink:href="abd-89-05-0806-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Several halos nevi (Sutton's nevi) of the trunk</p>
        </caption>
        <graphic xlink:href="abd-89-05-0806-g02"/>
      </fig>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 25-year-old Caucasian female with genital warts was treated with imiquimod 5% cream
three times weekly for 12 weeks .The treatment was well tolerated .At 4-month follow-up
after discontinuation, the patient was noted to have some residual condylomata and
marked depigmentation at the site of application.</p>
      <p>At 8-month follow-up she was noted do have developed halos of hypomelanosis around four
pre-existing nevi of the trunk . At 18 months follow-up the genital depigmentation
persisted and the halo nevi of the trunk were still present. Personal and family history
for melanoma, vitiligo and thyroid disorders were negative .Laboratory investigations,
including a panel of auto-antibodies, were performed without any significant abnormal
finding.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The case presented here was characterized by the co-existence of genital vitiligo-like
depigmentation and appearance of several halo nevi of the trunk. (<xref ref-type="fig" rid="f03">Figures 3</xref> and <xref ref-type="fig" rid="f04">4</xref>).<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Halo nevo in the left deltoid region</p>
        </caption>
        <graphic xlink:href="abd-89-05-0806-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Halo nevo of the trunk</p>
        </caption>
        <graphic xlink:href="abd-89-05-0806-g04"/>
      </fig>
      <p>Different mechanisms of imiquimod-induced depigmentation have been reported including
postinflammatory depigmentation, necrosis of melanocytes and immune mediated
vitiligo-like reactions.<sup><xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>As vitiligo may be expression of a cytotoxic T lymphocyte immune reaction, it may be
conceivable that imiquimod could contribute to the elimination of melanocytes by
inducing acquired immunity through the induction of cytokines.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>If this is true, it is likely that both vitiligo-like depigmentation at the site of
application and halo of hypomelanosis around melanocytic nevi of the trunk have been
induced by the same immunologic mechanism evoked by topical application of
imiquimod.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup></p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of Interests: None.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p>Financial Support: None</p>
      </fn>
      <fn fn-type="other">
        <p>How to cite this article: Serra MC, Menicanti C, Pennacchioli E, Tosti G. Vulvar
vitiligo-like depigmentation and multiple halos of hypomelanosis at the trunk
following treatment with imiquimod 5% cream for vulvar condylomata :casual or related
events? An Bras Dermatol. 2014;89(5)806-7.</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p>Work performed at the Divisione Melanoma, Istituto Europeo di Oncologia - Milano,
Italia.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Speeckaert</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>van Geel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Vermaelen</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Lambert</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Van Gele</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Speeckaert</surname>
              <given-names>MM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Immune reactions in benign and malignant melanocytic lesions: lessons
from immunotherapy</article-title>
          <source>Pigment Cell Melanoma Res</source>
          <year>2011</year>
          <volume>24</volume>
          <fpage>334</fpage>
          <lpage>344</lpage>
          <pub-id pub-id-type="pmid">21029398</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mashiah</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Possible mechanisms in the induction of vitiligo-like hypopigmentation
by topical imiquimod</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2008</year>
          <volume>33</volume>
          <fpage>74</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="pmid">17979992</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mendon&#xE7;a</surname>
              <given-names>CO</given-names>
            </name>
            <name>
              <surname>Yates</surname>
              <given-names>VM</given-names>
            </name>
          </person-group>
          <article-title>Permanent facial hypopigmentation following treatment with imiquimod
cream</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2006</year>
          <volume>31</volume>
          <fpage>721</fpage>
          <lpage>722</lpage>
          <pub-id pub-id-type="pmid">16780500</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stefanaki</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Nicolaidou</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hadjivassiliou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Antoniou</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Katsambas</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Imiquimodinduced vitiligo in a patient with genital
warts</article-title>
          <source>J Eur Acad Dermatol Venereol</source>
          <year>2006</year>
          <volume>20</volume>
          <fpage>755</fpage>
          <lpage>756</lpage>
          <pub-id pub-id-type="pmid">16836520</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gowda</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tillman</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Fitzpatrick</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Gaspari</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Goldenberg</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Imiquimod-induced vitiligo after treatment of nodular basal cell
carcinoma</article-title>
          <source>J Cutan Pathol</source>
          <year>2009</year>
          <volume>36</volume>
          <fpage>878</fpage>
          <lpage>881</lpage>
          <pub-id pub-id-type="pmid">19586497</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>SU</given-names>
            </name>
            <name>
              <surname>Hwang</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Pyun</surname>
              <given-names>JH</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Imiquimod induces apoptosis of human melanocytes</article-title>
          <source>Arch Dermatol Res</source>
          <year>2010</year>
          <volume>302</volume>
          <fpage>301</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="pmid">20033192</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ongenae</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Van Geel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Naeyaert</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Evidence for an autoimmune Pathogenesis of Vitiligo</article-title>
          <source>Pigment Cell Res</source>
          <year>2003</year>
          <volume>16</volume>
          <fpage>90</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="pmid">12622785</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
